Biogen Idec and Regulus Therapeutics Team Up for MS

A few weeks ago, Harvard researchers Drs. Oleg Butovsky and Howard Weiner announced the discovery of a potential miRNA-based biomarker for ALS. This week, Biogen Idec announced that it was teaming up with Regulus Therapeutics to identify a microRNA biomarker in blood for MS. A spokesperson for Regulus said the biomarker would be used to identify “optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.” Biogen Idec has a vested interest in using the biomarker for learning more about MS patient populations, as Biogen markets three MS drugs, Avonex, Fampyra and Tysabri.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail